TRENTON, N.J.: The U.S. Food and Drug Administration has rejected GlaxoSmithKline PLC's application to approve an experimental drug for nausea and vomiting.
The British drugmaker said Tuesday that it had received a "complete response letter" from the FDA regarding its application for casopitant.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!